Correlation Of Lipid Profile and Das28 Score of Early Rheumatoid Arthritis Patients on Conventional Synthetic Dmards
Article Sidebar
Main Article Content
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and a higher risk of cardiovascular diseases. The relationship between RA disease activity, lipid profiles, and the impact of disease-modifying antirheumatic drugs (DMARDs) on these parameters is an area of ongoing research.
Objective: This study aimed to investigate the correlation between lipid profiles and the Disease Activity Score in 28 joints (DAS-28) in patients with early RA who were on conventional synthetic DMARDs.
Methods: In this cross-sectional study, 30 RA patients from a rheumatology department were enrolled over six months. The study included adults aged 30-70 years, of both genders, who had been on DMARDs for at least 6 months. Exclusion criteria included fracture of the affected joint, pregnancy, use of steroids or lipid-lowering agents, and heavy smoking. Data on demographics, disease duration, type of DMARDs, and lipid profiles were collected. The DAS-28 score was calculated for each patient. Statistical analysis was performed using SPSS Version 25, with Pearson’s Correlation coefficient used to measure relationships between variables.
Results: The cohort consisted of 53.3% males and 46.7% females, with a mean age of 48.23 years. The majority (76.7%) were rheumatoid factor positive. The most commonly used DMARD was Methotrexate (46.7%). The study found strong negative correlations between DAS-28 scores and lipid levels: total cholesterol (Pearson's r = -0.837), triglycerides (r = -0.759), LDL (r = -0.720), and HDL (r = -0.689). BMI showed a significant positive correlation with DAS-28 (r = 0.711). A notable negative correlation was observed between the duration of DMARD use and DAS-28 scores (r = -0.777).
Conclusion: The study indicates a significant correlation between lipid profiles and disease activity in RA patients on DMARDs. The findings suggest that effective RA management with DMARDs could influence lipid metabolism and potentially reduce cardiovascular risks. These insights are crucial for developing comprehensive RA treatment strategies that encompass both joint health and cardiovascular considerations.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Benjamin O, Goyal A, Lappin SL. Disease-Modifying Antirheumatic Drugs (DMARD). Treasure Island (FL): StatPearls Publishing; 2023.
Joo YB, Jung SM, Park Y-J, Kim K-J, Park K-S. Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients. J Rheum Dis. 2022;29(3):162-70.
AbouAssi H, Connelly MA, Bateman LA, Tune KN, Huebner JL, Kraus VB, et al. Does a lack of physical activity explain the rheumatoid arthritis lipid profile? Lipids in Health and Disease. 2017;16(1):39.
Lei Q, Yang J, Li L, Zhao N, Lu C, Lu A, et al. Lipid metabolism and rheumatoid arthritis. Frontiers in Immunology. 2023;14.
Bag-Ozbek A, Giles JT. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Current allergy and asthma reports. 2015;15:1-10.
Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2015;33(1):115-21.
Erum U, Ahsan T, Khowaja D. Lipid abnormalities in patients with Rheumatoid Arthritis. Pak J Med Sci. 2017;33(1):227-30.
Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, et al. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment. Mediators Inflamm. 2018;2018:2453265.
Koh JH, Lee BW, Kim WU. Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors. J Rheum Dis. 2023;30(4):234-42.
Radu A-F, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857.
Greenmyer JR, Stacy JM, Sahmoun AE, Beal JR, Diri E. DAS28‐CRP cutoffs for high disease activity and remission are lower than DAS28‐ESR in rheumatoid arthritis. ACR Open Rheumatology. 2020;2(9):507-11.
Paulson A, Abraham FA, Davis F, Ranji NM, Panayappan KKL. Assessment of Disease Severity in Rheumatoid Arthritis Patients Using Das28, Cdai, Raad Score and Rapid-3–A Review. International Journal of Multidisciplinary and Current Educational Research. 2021;3(2):146-8.
Kim YJ, Nazir N, Aronov A. Association of Systemic Inflammation with Lipid Profiles and Management in Patients with Rheumatoid Arthritis. Journal of Clinical Lipidology. 2022;16(3):e58-e9.
Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmunity reviews. 2020;19(6):102528.
Behl T, Kaur I, Sehgal A, Zengin G, Brisc C, Brisc MC, et al. The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. International journal of molecular sciences. 2020;21(24):9505.
Papamichail GV, Markatseli TE, Georgiadis A, Xydis VG, Milionis HJ, Drosos AA, et al. THU0132 EVALUATION OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICAL AGENTS: 3-MONTH FOLLOW-UP. Annals of the Rheumatic Diseases. 2019;78:338 - 9.
Taylan AS, Akıncı B, Toprak B, Birlik M, Arslan FD, Ekerbiçer HÇ, et al. Association of Leptin Levels and Disease Activity in Patients with Early Rheumatoid Arthritis. Archives of medical research. 2021.
Aletaha D, Maa J-f, Chen S, Park S-H, Nicholls D, Florentinus SR, et al. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2019;78:1609 - 15.
karimifar m, Sepehrifar MS, Moussavi H, Sepehrifar MB, Mottaghi P, Siavash M, et al. The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids. Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences. 2018;23.
Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study. Arthritis Research & Therapy. 2006;8(3):R82.
Chen D-Y, Chen Y-M, Hsieh T-Y, Hsieh C-W, Lin C-C, Lan J-L. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Research & Therapy. 2015;17(1):52.